Global demand for protein will double in the next few decades. The only way to meet this demand in a way that is both respectful of animal well being and preserves or increases wild spaces is to make livestock that are better adapted to their environment, and which use fewer resources to produce the same amount of protein. In this way, their solutions can help the livestock, the planet, and the producer, all at the same time. See the video presentation or the links below for an overview of their current projects.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Artemis Pharma, Inc. provides health care services. It develops agents for the prevention and treatment of severe and potentially life-threatening infectious diseases. The company is headquartered in United States. Therapeutics

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

Beijing Jifulin Biotechnology Co., Ltd., established on 2009-12-25, Business scope includes technology development,technology transfer,technical consulting,Technical Services,Technology Promotion;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Agricultural Science Research and Experimental Development;Medical Research and Experimental Development;sell cosmetics,fertilizer.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Tokyo Metropolitan Institute of Medical Science is a Japanese private company. The firm operates as a research institute that develops medicine.

At the beginning of the twentieth century, tuberculosis was one of the UK’s most urgent health problems. A royal commission, entitled The Royal Commission Appointed to Inquire into the Relations of Human and Animal Tuberculosis, was set up in 1901. It aimed to find out whether tuberculosis in animals and humans was the same disease and whether animals and humans could infect each other. This page describes how, by 1919, the Commission had evolved into the independent Medical Research Council.

Zhongji Zhiyao (Nanjing) Biotechnology Co., Ltd., established on 2020-09-08, Business scope includes licensed projects:Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:R&D and application of cell technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;software development;Conference and Exhibition Services;Health Consulting Services(Does not include medical services);Sales of Class I Medical Devices;Sales of Class II Medical Devices;Chemical product sales(No licensed chemical products);Specialty Chemicals Sales(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help their clients realize their research goals in the rapidly evolving world of genomics. The company has become a world-leader in NGS services, with 1,800 employees and multiple locations across the globe. Novogene’s depth of experience has resulted in the ownership of 49 NGS-related patents, as well as the publishing of over 1850 customer research papers, often in well-respected publications such as Nature and Science. Company founder, Dr. Ruiqiang Li, is widely recognized as one of the world’s leading experts in genomics and bioinformatics, owning 12 patents and authoring over 90 peer-reviewed publications that have been cited >15,000 times. Best known for developing the software SOAP (Short Oligonucleotide Analysis Package) for ultra-fast sequence mapping, variation detection, and de novo genome assembly, Dr. Li has focused Novogene’s services on performing sequencing AND providing informatics to fully empower and enable their customers to move forward rapidly and effectively in their scientific endeavors.

Zhenjiang Jieshengrui Technology Co., Ltd., established on 2019-03-29, Business scope includes medical technology,Technology development in the field of biotechnology,technical consulting,technology transfer,Technical Services,Technology Promotion;Research and development of biological reagents;R&D of medical devices,Production,Sales,Technical Services,technical consulting;computer software development,Sales;Online Trade Agent;Business Management Consulting;Intellectual Property Agency Consulting Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Yangling Keyuan Clone Co., Ltd., established on 2001-02-18, The business scope includes fine-bred beef cattle,the cow,sheep and its embryos,frozen semen,Production and sales of biological products;Embryo Engineering Technical Services;Technology Consulting.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Tapestry Pharmaceuticals, Inc. develops, manufactures, and markets an anti-cancer pharmaceutical called Paclitaxel. It focuses on the development of proprietary therapies for the treatment of cancer, new products and technologies may involve the examination of individual molecules and classes of compounds. The company was founded in 1991 and is headquartered in Ankeny, IA.

Incorporated in late 2005, VitamFero SA is a privately held biotech company whose mission, founded on an innovative and patented technology (i.e. Toxo KO), is to create, develop, register and market novel anti-infectious vaccines, first against Apicomplexe parasites such as: - Toxoplasma gondii (toxoplasmosis agent) - Neospora caninum (neosporosis agent) - Cryptosporidium parvum (cryptosporidiosis agent). With headquarters in Evry (France) and laboratories in Tours (France), VitamFero is involved first in veterinary healthcare.

Tianjin Medical University General Hospital (Chinese: 天津医科大学总医院) is a general hospital in the central Heping District of the Chinese metropolis of Tianjin, associated with Tianjin Medical University.